Revelation Biosciences, Inc., (REVB): Price and Financial Metrics
GET POWR RATINGS... FREE!
REVB Stock Price Chart Interactive Chart >
REVB Price/Volume Stats
| Current price | $10.35 | 52-week high | $100.80 |
| Prev. close | $10.50 | 52-week low | $5.91 |
| Day low | $9.14 | Volume | 126,100 |
| Day high | $11.17 | Avg. volume | 28,116 |
| 50-day MA | $7.86 | Dividend yield | N/A |
| 200-day MA | $16.23 | Market Cap | 243.60M |
Revelation Biosciences, Inc., (REVB) Company Bio
Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company's lead therapeutic candidate is REVTx-99, an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses, such as SARS-CoV-2 comprising its variants, influenza A and B, parainfluenza, rhinovirus, and RSV, as well as is being developed for other indications comprising allergic rhinitis and chronic nasal congestion. It also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for immunity; and REVDx-501, a rapid home use diagnostic to detect respiratory viral infection. The company was founded in 2019 and is based in New York, New York.
Latest REVB News From Around the Web
Below are the latest news stories about REVELATION BIOSCIENCES INC that investors may wish to consider to help them evaluate REVB as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about for Tuesday morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayWe're starting off the day with an overview of the biggest pre-market stock movers traders need to know about for Friday morning! |
Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical ModelSAN DIEGO, Calif., November 18, 2022--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced that recently completed exploratory biomarker analysis has confirmed clinical development plans for REVTx-300 in the treatment of CKD and AKI. This new biomarker data is in addition to the previously-announced significant reduction in |
Revelation Biosciences Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Recent Corporate ProgressSAN DIEGO, November 10, 2022--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its third quarter 2022 financial results and highlighted recent corporate progress. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're starting off the day with a look at the latest news behind the biggest pre-market stock movers for Thursday morning! |
REVB Price Returns
| 1-mo | 51.26% |
| 3-mo | 21.84% |
| 6-mo | -41.52% |
| 1-year | -88.12% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 55.56% |
| 2022 | -98.14% |
| 2021 | 1.49% |
| 2020 | -74.36% |
| 2019 | 37.54% |
| 2018 | 1.60% |
Loading social stream, please wait...